Clinical trial · Observational
CirculAting Tumor DNA in Patients DIagnosed With Lung Metastasis From Colorectal Cancer: candiDate Selection for Local AblaTive thErapy
NCT04704960CI-TRIAL-00049422CANDIDATEunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators will detect circulating tumor DNA in blood of patients with lung metastases from colorectal cancer using NGS technology and intend to use it for predicting the outcome of local treatment (surgery or radiation) and recurrence of lung metastases.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Lung Metastases | Colorectal Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Diagnostic Test: liquid biopsy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Lung metastases from colorectal cancer, local ablative therapy (surgery or radiation)
- description
- patients diagnosed with lung metastases from colorectal cancer and undergoing surgery or radiation for lumg metastasis
- interventionNames
- Other: Diagnostic Test: liquid biopsy
Primary outcomes (1)
- measure
- correlation between circulating tumor DNA (ctDNA) before and after local treatment (surgery or radiation) and recurrence of lung metastases from colorectal cancer
- timeFrame
- about 6 month but additional extension for patients with relapse after local treatment
- description
- The investigations investigate whether ctDNA changes and f/u ctDNA fraction after local treatment (surgery or radiation) can be useful as markers to predict the outcome of local treatments.
Secondary outcomes (1)
- measure
- mutations related to target drug
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: 1. adults over 19 years of age 2. those who understand research and have written consent 3. cases diagnosed with lung metastases from colorectal cancer Exclusion Criteria: 1. pregnant women, nursing women 2. those who lack the ability to voluntarily agree 3. participation in other clinical trials where drugs for clinical trials are administered within the past four weeks as of the date of participation in clinical trials
References
Publications (0)
Data not yet available
No reference posted for this study.